'Criteria' aPL tests

Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010

S. S. Pierangeli, P. G. De Groot, J. Dlott, E. Favaloro, E. N. Harris, G. Lakos, T. Ortel, P. L. Meroni, Kotaro Otomo, V. Pengo, A. Tincani, R. Wong, R. Roubey

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Current classification criteria for definite antiphospholipid syndrome (APS) mandate the use of one or more of three positive 'standardized' laboratory assays to detect antiphospholipid antibodies (aPL) (viz: anticardiolipin [aCL] IgG and IgM; anti-β2glycoprotein I [anti-β2GPI] antibodies IgG and IgM; and/or a lupus anticoagulant [LAC]), when at least one of the two major clinical manifestations (thrombosis or pregnancy losses) are present. Although, efforts of standardization for these 'criteria' aPL tests have been conducted over the last 27 years, reports of inconsistencies, inter-assay and inter-laboratory variation in the results of aCL, LAC, and anti-β2GPI, and problems with the interpretation and the clinical value of the tests still exist, which affect the consistency of the diagnosis of APS. A Task Force of scientists and pioneers in the field from different countries, subdivided in three working groups, discussed and analyzed critical questions related to 'criteria' aPL tests in an evidence-based manner, during the 13th International Congress on Antiphospholipid Antibodies (APLA 2010, April 13-16, 2010, Galveston, TX). These included: review of the standardization and the need for international consensus protocol for aCL and anti-β2GPI tests; the use of monoclonal and/or polyclonal standards in the calibration curve of those tests; and the need for establishment of international units of measurement for anti- β2GPI tests. The group also reviewed the recently updated guidelines for LAC testing, and analyzed and discussed the possibility of stratification of 'criteria' aPL tests as risk factors for APS, as well as the clinical value of single positive vs. multiple aPL positivity. The group members presented, discussed, analyzed data, updated and re-defined those critical questions at a preconference workshop that was open to congress attendees. This report summarizes the findings, conclusions, and recommendations of this Task Force.

Original languageEnglish
Pages (from-to)182-190
Number of pages9
JournalLupus
Volume20
Issue number2
DOIs
Publication statusPublished - 2011 Feb 1
Externally publishedYes

Fingerprint

Antiphospholipid Antibodies
Advisory Committees
Education
Lupus Coagulation Inhibitor
Antiphospholipid Syndrome
Calibration
Immunoglobulin M
Thrombosis
Immunoglobulin G
Guidelines
Pregnancy
Antibodies

Keywords

  • anti-βGlycoprotein I antibodies
  • Anticardiolipin antibodies
  • Antiphospholipid Syndrome
  • lupus anticoagulant
  • standardization

ASJC Scopus subject areas

  • Rheumatology

Cite this

'Criteria' aPL tests : Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. / Pierangeli, S. S.; De Groot, P. G.; Dlott, J.; Favaloro, E.; Harris, E. N.; Lakos, G.; Ortel, T.; Meroni, P. L.; Otomo, Kotaro; Pengo, V.; Tincani, A.; Wong, R.; Roubey, R.

In: Lupus, Vol. 20, No. 2, 01.02.2011, p. 182-190.

Research output: Contribution to journalArticle

Pierangeli, SS, De Groot, PG, Dlott, J, Favaloro, E, Harris, EN, Lakos, G, Ortel, T, Meroni, PL, Otomo, K, Pengo, V, Tincani, A, Wong, R & Roubey, R 2011, ''Criteria' aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010', Lupus, vol. 20, no. 2, pp. 182-190. https://doi.org/10.1177/0961203310395055
Pierangeli, S. S. ; De Groot, P. G. ; Dlott, J. ; Favaloro, E. ; Harris, E. N. ; Lakos, G. ; Ortel, T. ; Meroni, P. L. ; Otomo, Kotaro ; Pengo, V. ; Tincani, A. ; Wong, R. ; Roubey, R. / 'Criteria' aPL tests : Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. In: Lupus. 2011 ; Vol. 20, No. 2. pp. 182-190.
@article{22657dffb2204c27aef5ce023153fe0d,
title = "'Criteria' aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010",
abstract = "Current classification criteria for definite antiphospholipid syndrome (APS) mandate the use of one or more of three positive 'standardized' laboratory assays to detect antiphospholipid antibodies (aPL) (viz: anticardiolipin [aCL] IgG and IgM; anti-β2glycoprotein I [anti-β2GPI] antibodies IgG and IgM; and/or a lupus anticoagulant [LAC]), when at least one of the two major clinical manifestations (thrombosis or pregnancy losses) are present. Although, efforts of standardization for these 'criteria' aPL tests have been conducted over the last 27 years, reports of inconsistencies, inter-assay and inter-laboratory variation in the results of aCL, LAC, and anti-β2GPI, and problems with the interpretation and the clinical value of the tests still exist, which affect the consistency of the diagnosis of APS. A Task Force of scientists and pioneers in the field from different countries, subdivided in three working groups, discussed and analyzed critical questions related to 'criteria' aPL tests in an evidence-based manner, during the 13th International Congress on Antiphospholipid Antibodies (APLA 2010, April 13-16, 2010, Galveston, TX). These included: review of the standardization and the need for international consensus protocol for aCL and anti-β2GPI tests; the use of monoclonal and/or polyclonal standards in the calibration curve of those tests; and the need for establishment of international units of measurement for anti- β2GPI tests. The group also reviewed the recently updated guidelines for LAC testing, and analyzed and discussed the possibility of stratification of 'criteria' aPL tests as risk factors for APS, as well as the clinical value of single positive vs. multiple aPL positivity. The group members presented, discussed, analyzed data, updated and re-defined those critical questions at a preconference workshop that was open to congress attendees. This report summarizes the findings, conclusions, and recommendations of this Task Force.",
keywords = "anti-βGlycoprotein I antibodies, Anticardiolipin antibodies, Antiphospholipid Syndrome, lupus anticoagulant, standardization",
author = "Pierangeli, {S. S.} and {De Groot}, {P. G.} and J. Dlott and E. Favaloro and Harris, {E. N.} and G. Lakos and T. Ortel and Meroni, {P. L.} and Kotaro Otomo and V. Pengo and A. Tincani and R. Wong and R. Roubey",
year = "2011",
month = "2",
day = "1",
doi = "10.1177/0961203310395055",
language = "English",
volume = "20",
pages = "182--190",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - 'Criteria' aPL tests

T2 - Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010

AU - Pierangeli, S. S.

AU - De Groot, P. G.

AU - Dlott, J.

AU - Favaloro, E.

AU - Harris, E. N.

AU - Lakos, G.

AU - Ortel, T.

AU - Meroni, P. L.

AU - Otomo, Kotaro

AU - Pengo, V.

AU - Tincani, A.

AU - Wong, R.

AU - Roubey, R.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Current classification criteria for definite antiphospholipid syndrome (APS) mandate the use of one or more of three positive 'standardized' laboratory assays to detect antiphospholipid antibodies (aPL) (viz: anticardiolipin [aCL] IgG and IgM; anti-β2glycoprotein I [anti-β2GPI] antibodies IgG and IgM; and/or a lupus anticoagulant [LAC]), when at least one of the two major clinical manifestations (thrombosis or pregnancy losses) are present. Although, efforts of standardization for these 'criteria' aPL tests have been conducted over the last 27 years, reports of inconsistencies, inter-assay and inter-laboratory variation in the results of aCL, LAC, and anti-β2GPI, and problems with the interpretation and the clinical value of the tests still exist, which affect the consistency of the diagnosis of APS. A Task Force of scientists and pioneers in the field from different countries, subdivided in three working groups, discussed and analyzed critical questions related to 'criteria' aPL tests in an evidence-based manner, during the 13th International Congress on Antiphospholipid Antibodies (APLA 2010, April 13-16, 2010, Galveston, TX). These included: review of the standardization and the need for international consensus protocol for aCL and anti-β2GPI tests; the use of monoclonal and/or polyclonal standards in the calibration curve of those tests; and the need for establishment of international units of measurement for anti- β2GPI tests. The group also reviewed the recently updated guidelines for LAC testing, and analyzed and discussed the possibility of stratification of 'criteria' aPL tests as risk factors for APS, as well as the clinical value of single positive vs. multiple aPL positivity. The group members presented, discussed, analyzed data, updated and re-defined those critical questions at a preconference workshop that was open to congress attendees. This report summarizes the findings, conclusions, and recommendations of this Task Force.

AB - Current classification criteria for definite antiphospholipid syndrome (APS) mandate the use of one or more of three positive 'standardized' laboratory assays to detect antiphospholipid antibodies (aPL) (viz: anticardiolipin [aCL] IgG and IgM; anti-β2glycoprotein I [anti-β2GPI] antibodies IgG and IgM; and/or a lupus anticoagulant [LAC]), when at least one of the two major clinical manifestations (thrombosis or pregnancy losses) are present. Although, efforts of standardization for these 'criteria' aPL tests have been conducted over the last 27 years, reports of inconsistencies, inter-assay and inter-laboratory variation in the results of aCL, LAC, and anti-β2GPI, and problems with the interpretation and the clinical value of the tests still exist, which affect the consistency of the diagnosis of APS. A Task Force of scientists and pioneers in the field from different countries, subdivided in three working groups, discussed and analyzed critical questions related to 'criteria' aPL tests in an evidence-based manner, during the 13th International Congress on Antiphospholipid Antibodies (APLA 2010, April 13-16, 2010, Galveston, TX). These included: review of the standardization and the need for international consensus protocol for aCL and anti-β2GPI tests; the use of monoclonal and/or polyclonal standards in the calibration curve of those tests; and the need for establishment of international units of measurement for anti- β2GPI tests. The group also reviewed the recently updated guidelines for LAC testing, and analyzed and discussed the possibility of stratification of 'criteria' aPL tests as risk factors for APS, as well as the clinical value of single positive vs. multiple aPL positivity. The group members presented, discussed, analyzed data, updated and re-defined those critical questions at a preconference workshop that was open to congress attendees. This report summarizes the findings, conclusions, and recommendations of this Task Force.

KW - anti-βGlycoprotein I antibodies

KW - Anticardiolipin antibodies

KW - Antiphospholipid Syndrome

KW - lupus anticoagulant

KW - standardization

UR - http://www.scopus.com/inward/record.url?scp=79953299697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953299697&partnerID=8YFLogxK

U2 - 10.1177/0961203310395055

DO - 10.1177/0961203310395055

M3 - Article

VL - 20

SP - 182

EP - 190

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 2

ER -